BeOne Medicines Ltd. Files 8-K on Financials
Ticker: BEIGF · Form: 8-K · Filed: Aug 29, 2025 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beone Medicines LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
Related Tickers: BGNE
TL;DR
BeOne Medicines filed its 8-K for Aug 29, 2025, covering financials and exhibits.
AI Summary
BeOne Medicines Ltd. filed an 8-K on August 29, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as BeiGene, Ltd. until August 19, 2015, is incorporated in Switzerland and has its principal executive offices in Basel.
Why It Matters
This filing provides investors with an update on BeOne Medicines Ltd.'s operational and financial status, including any new financial statements or exhibits.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- BeOne Medicines Ltd. (company) — Registrant
- August 29, 2025 (date) — Date of Report
- BeiGene, Ltd. (company) — Former Company Name
- August 19, 2015 (date) — Date of Name Change
- Switzerland (location) — Jurisdiction of Incorporation
- Basel (location) — City of Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was BeOne Medicines Ltd. formerly known as BeiGene, Ltd.?
The company was formerly known as BeiGene, Ltd. until August 19, 2015.
Where are BeOne Medicines Ltd.'s principal executive offices located?
The principal executive offices are located in Basel, Switzerland.
What is the SEC Act under which this report is filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for BeOne Medicines Ltd.?
The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Filing Stats: 897 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2025-08-29 06:52:29
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share ONC The NASDAQ Global Selec
Filing Documents
- bgne-20250829.htm (8-K) — 37KB
- a20250829formxstarinterimr.htm (EX-99.1) — 21KB
- 0001651308-25-000136.txt ( ) — 175KB
- bgne-20250829.xsd (EX-101.SCH) — 2KB
- bgne-20250829_lab.xml (EX-101.LAB) — 21KB
- bgne-20250829_pre.xml (EX-101.PRE) — 12KB
- bgne-20250829_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 29, 2025, BeiGene, Ltd. (the "Company") filed its 2025 Interim Report for the six months ended June 30, 2025 (the "STAR Interim Report") with the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples' Republic of China (the "PRC" and the "PRC Securities Laws"). As required by the PRC Securities Laws, the STAR Interim Report contains additional financial information of the Company for the six months ended June 30, 2025 (the "Reporting Period"), prepared in accordance with the China Accounting Standards for Business Enterprises – Basic Standard ("CAS") and other applicable PRC accounting rules, guidance and interpretations (together with CAS, "PRC GAAP"). As required by the PRC Securities Laws, the STAR Interim Report also contains financial information of the Company for the Reporting Period prepared in accordance with PRC GAAP. PRC GAAP are different from accounting principles generally accepted in the United States ("U.S. GAAP"). The financial information regarding the Company's research and development expenses allocated by key products and other research and development projects for the Reporting Period prepared in accordance with U.S. GAAP as well as a summary of the material differences between PRC GAAP and U.S. GAAP are attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The STAR Interim Report is available to the public in Chinese language only on the website maintained by the Shanghai Stock Exchange at www.sse.com.cn. The STAR Interim Report and the information contained on the Shanghai Stock Exchange's website are not part of this Current Report on Form 8-K and shall not be deemed filed or furnished by the Company with the U.S. Securities and Exchange Commi
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Financial Information, furnished herewith 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 99.1 Financial Information, furnished herewith 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEONE MEDICINES LTD. Date: August 29, 2025 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel